Polycystic Ovarian Disease

DESCRIPTION
Polycystic ovarian disease (PCOD) is characterized by a state of chronic oligo-ovulation and/or anovulation culminating in oligomenorrhea and/or amenorrhea
  • System(s) affected: Reproductive, Endocrine/Metabolic, Skin/Exocrine
  • Genetics: Probably transmitted genetically, especially if associated with 21-hydroxylase deficiency or other enzyme deficiencies
  • Incidence/Prevalence in USA: Unknown, but is a common cause of oligomenorrhea and/or amenorrhea
  • Predominant age: Women of reproductive age
  • Predominant sex: Female only
SIGNS AND SYMPTOMS
  • Amenorrhea
  • Oligomenorrhea
  • Obesity
  • Hirsutism
  • Acne
  • Dysfunctional uterine bleeding
  • Infertility
  • Acanthosis nigricans
  • Hypertension
  • Virilism
  • Enlarged ovaries
  • Enlarged clitoris
  • Deep voice
CAUSES
Disruption of hypothalamic-pituitary-ovarian axis (high normal luteinizing hormone and low normal follicle stimulating hormone leading to ovarian hyperandrogenism and follicular atresia and anovulation) or secondary to increased levels of insulin or increased sensitivity to normal levels of insulin
RISK FACTORS
  • Endometrial hyperplasia
  • Endometrial carcinoma
  • Obesity
  • Hypertension
  • Diabetes mellitus
  • Breast cancer
  • Infertility
LABORATORY
  • Luteinizing hormone/follicle stimulating hormone (LH/FSH) ≥ 2.5-3.0/1
  • Testosterone increased, but less than 200 ng/dL (6.94 nmol/L)
  • Dehydroepiandrosterone sulfate (DHEA-S) increased, but less than 800 µg/dL (20.8 µmol/L)
  • Dehydroepiandrosterone (DHEA) increased
  • 17-OH progesterone increased
  • Estrone increased
  • Androstenedione increased
  • Sex hormone binding globulin decreased
  • Prolactin increased slightly
Drugs that may alter lab results:
  • Oral contraceptives
  • Steroids
  • Antidepressants
Disorders that may alter lab results: N/A
PATHOLOGICAL FINDINGS
  • Ovary usually enlarged with a smooth white glistening capsule
  • Ovarian cortex lined with follicles in all stages of development but most are atretic
  • Theca cell proliferation with an increase in the stromal compartment
SPECIAL TESTS
  • Fasting serum glucose and insulin level to rule out insulin resistance and glucose intolerance
  • Overnight dexamethasone suppression test (Decadron 1 mg po at 11:00PM and fasting serum cortisol at 8:00AM the next morning) to rule out Cushing's syndrome
IMAGING
Pelvis ultrasound revealing enlarged ovaries with multiple small follicular cysts
DIAGNOSTIC PROCEDURES
  • History and physical examination
  • Endometrial biopsy to rule out hyperplasia and or carcinoma
APPROPRIATE HEALTH CARE
  • Outpatient
  • Inpatient, if surgery for wedge resection recommended
GENERAL MEASURES

No ideal treatment exists. Treatment must be individualized according to the needs and desires of the patient.

SURGICAL MEASURES

N/A

ACTIVITY

Full activity

DIET

Regular (weight loss recommended, if overweight)

PATIENT EDUCATION

Counsel the patient regarding the risk of endometrial and breast carcinoma, insulin resistance and diabetes mellitus, obesity and infertility

PREVENTION/AVOIDANCE

Prevent endometrial and breast carcinoma

POSSIBLE COMPLICATIONS
  • Multiple pregnancies
  • Ovarian hyperstimulation syndrome (OHS)
  • Oral contraceptives are not without risk
EXPECTED COURSE AND PROGNOSIS
  • Prognosis for fertility is excellent depending upon other fertility factors
  • Proper treatment and followup of chronic anovulation, can prevent endometrial hyperplasia and/or carcinoma
ASSOCIATED CONDITIONS
  • Obesity
  • Hypertension
  • Endometrial hyperplasia and/or carcinoma
  • Breast carcinoma
  • Diabetes mellitus
  • Hairan syndrome
  • Infertility
  • Hyperthecosis
AGE-RELATED FACTORS

Pediatric: May begin at puberty
Geriatric: N/A
Others: N/A

PREGNANCY

Does not cure the syndrome

OTHER NOTES
  • Drug costs high
  • Monitoring (ultrasounds, estradiols) costs high
ABBREVIATIONS

OHS = ovarian hyperstimulation syndrome
HMG = human menopausal gonadotropins
FSH = follicle stimulating hormone

Clinical Investigations

ROLE OF HOMOEOPATHY

Copyright © 2025 Selkey. All Rights Reserved.